Objectives: To measure the level of YKL-40 in COVID-19 patients with and without skin lesion in Elbagour Hospital.
Background: The outbreak of coronavirus disease 2019 (COVID-19), caused by
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has
emerged in China in December 2019 and rapidly spread to more than 196 countries worldwide.
Methods: A case-control study was conducted on a total number of 180 patients
including 60 COVID -19 patients with skin manifestations and 60 COVID- 19 patients without skin manifestations besides 60 age and gender-matched healthy subjects as a control group. The patients were those attending El-Bagour Hospital COVID- 19 isolation from March 2020 to March 2021. Diagnosis of COVID-19 was done clinically and by laboratory investigations, confirmed by PCR.
Results: The mean levels of YKL-40 were significantly higher in COVID-19 patients than in the controls (66.47 ± 66.52 ng/ml vs 17.25 ± 3.16 ng/ml). The mean levels of YKL-40 were significantly higher in COVID-19 patients with cutaneous
manifestations than those without cutaneous manifestations (94.85 ± 84.50 ng/ml vs 38.09 ± 12.12 ng/ml).
Conclusion: The mean level of YKL-40 was significantly higher in COVID-19
patients especially severe cases than the controls and in COVID-19 patients with
cutaneous manifestations than those without cutaneous manifestations.
Farag, Azza G.; Badr, Eman A.; Tayel, Eman A.; and Elshafey, Eman N.
"YKL-40 Serum Level in COVID-19 Patients Having Skin Manifestations,"
Menoufia Medical Journal: Vol. 36:
1, Article 10.